Want to know more?

To speak to us about Retinal treatments or to book a consultation, please get in touch.

Prof. Paulo E. Stanga

Prof. Paulo E. Stanga is a Consultant Ophthalmologist & Vitreoretinal Surgeon (Manchester Royal Eye Hospital – NHS), Professor of Ophthalmology and Retinal Regeneration (Univ. of Manchester – Research) and has worked in Ophthalmology for over 26 years.

As a leading Vitreo-Retinal Specialist, Prof. Stanga routinely treats within the Private Sector all conditions affecting the vitreous, retina and macula in both adults and children.

Prof. Stanga is also a Cataract Surgeon who not only offers Cataract Surgery himself but also specializes in the medical and surgical management of Complications of Cataract Surgery.

Prof. Stanga has a personal interest in Ocular Trauma and is routinely asked to provide ophthalmic care to Rugby, Football and Polo players, amongst others, being personally involved with the three sports.

Prof. Stanga has significantly contributed towards the field of Retinal Imaging, Tissue-Sparing Retinal Laser Techniques and the introduction and development of new technologies for Vitrectomy Surgery such as Small Gauge Sutureless and Hypersonic Vitrectomy, as well as the Argus II® Electronic Epiretinal Implant (Bionic Eye) for Artificial Vision.

Prof. Stanga is Scientific Advisor and Consultant to several commercial companies that develop pharmacological therapies, diagnostic or therapeutic equipment.

Speciality:

  • Ophthalmology: Medical and Surgical Retina, Eye Trauma and Cataract Surgery and its Complications
  • Cataract and Lens extraction surgery: Phacoemulsification surgery with implantation of Intraocular Lens
  • Complications of Cataract surgery
  • Laser Capsulotomy (YAG LASER)
  • Wet Age-related Macular Degeneration: Intravitreal Injections (anti-VEGF; Avastin®, Lucentis®, Eylea®)
  • Diabetic Retinopathy and Maculopathy: Intravitreal Injections (anti-VEGF: Avastin®, Lucentis®, Eylea® or Steroid: Triamcinolone®, Triesence®, Ozurdex®), LASER (PASCAL® laser) or Vitrectomy surgery
  • Retinal Vein Occlusion: laser (PASCAL® LASER) and /or intravitreal injections
  • Retinal Tears: LASER Retinopexy
  • Retinal Detachment: Cryo-Buckle or Pars Plana Vitrectomy surgery
  • Macular Hole Pars Plana Vitrectomy surgery without prolonged positioning or Intravitreal Injection of Occriplasmin (Jetrea®)
  • Epiretinal Membranes (macular pucker): Pars Plana Vitrectomy surgery
  • Vitreous Floaters: Pars Plana Vitrectomy surgery
  • Retinitis Pigmentosa: Argus II® Electronic Retinal Implant (Bionic Eye) for Artificial Vision

Qualifications

Professional memberships:

  • British Medical Association
  • General Medical Council
  • Royal College of Ophthalmologists
  • America Academy of Ophthalmologists
  • Association for Research in Vision and Ophthalmology
  • American Society of Retinal Specialists
  • British and Eire Association of Vitreoretinal Surgeons

Prof. Stanga is Fully Registered Medical Practitioner with Specialist Registration, GMC, UK

GMC Reference No 4759748

Previous appointments include: Lecturer in Ophthalmology for the University of Liverpool, Vitreoretinal Fellow at the Royal Liverpool University Hospital, Medical Retina Fellow at Moorfields Eye Hospital and Retina Research Fellow, New York Hospital, Cornell University Medical College, New York, USA.

Since 1993, Prof. Stanga has worked in the development and application of new outpatient and surgical therapies and technologies and is Principal Investigator (PI) on several industry-sponsored trials and Scientific Advisor to commercial companies that develop pharmacological/surgical therapies, diagnostic/therapeutic equipment.

Prof. Stanga has introduced OCT into the clinical setting in the UK (1998), Pascal® Laser into the EU (2006), pioneered Optos® Ultra Wide-Field Imaging (2006) and introduced Swept-Source OCT into the EU (2012).

Current research interests: Vitreo-Retinal Imaging, Laser-Tissue Interaction and new Tissue-Sparing Laser Photocoagulation Techniques, Development of Hypersonic Vitrectomy Equipment, Electronic Retinal Implants (Bionic Eye)/Artificial Vision, Stem-Cell and Gene Therapy.

Prof. Stanga has set-up and is PI for a Manchester-only Pilot Study of the Argus II system in Age-Related Macular Degeneration (AMD) and has successfully carried out the first ever implantations of an electronic retinal implant in AMD, which have resulted in the first ever persons with integrated artificial (central) and natural (peripheral) vision.

Prof. Stanga has also played a successful and significant role working with NHS England for the Argus II system to be funded and evaluated in patients with advanced Retinitis Pigmentosa and making this the first use of Artificial Vision in the NHS (2016).

Prof. Stanga is the Manchester Royal Eye Hospital Principal Investigator for Gene Therapy trials in Choroideremia and Retinitis Pigmentosa.

Prof. Stanga has set up and is Director of the Manchester Vision Regeneration (MVR) Lab at NIHR/Wellcome Trust Manchester CRF and its Clinical, Surgical and Research Fellowship Program and which focuses on Innovation, developing new diagnostic and treatment devices & techniques.

Prof. Stanga is a frequently Invited Speaker at National and International scientific and surgical meetings.

Prof. Stanga has received several international accolades, amongst others, the prestigious Award for Outstanding Contribution to Ophthalmology in Singapore (Singapore, 2006), Award in Appreciation for Support and Far Reaching Contributions at the NGH Eye Institute (Singapore, 2008), American Academy of Ophthalmology Achievement Award (USA, 2011), Outstanding Personality in Science by the City Council (Legislatura Portena) of the city of Buenos Aires (Argentina, 2012), Award for Outstanding Contribution to Retinology in Poland (Krakow, 2014).

Prof. Paulo E. Stanga